Traws Pharma, Inc.

Traws Pharma, Inc. has updated its At The Market (ATM) Offering Agreement with Citizens JMP Securities, LLC, allowing the company to offer and sell shares of its common stock. Initially, the agreement permitted sales up to $50,000,000. Under a new prospectus supplement dated July 10, 2026, the company may now sell shares with an aggregate offering price of up to $5,575,709, utilizing its effective shelf registration statement on Form S-3.

Traws Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 8, 2026, where several key proposals were approved. Stockholders voted to amend the 2021 Incentive Compensation Plan, increasing the number of shares available for issuance by 2,000,000. Additionally, seven directors were elected, KPMG LLP was ratified as the independent auditor for 2026, and the issuance of common stock for Series B and C Warrants was approved.

Traws Pharma announced its intention to resubmit an updated data package to the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for the planned testing of tivoxavir marboxil (TXM). This resubmission, which includes updated toxicology and preclinical safety information, is for a Phase 2a human influenza Challenge study and is expected in the third quarter of 2026. The company anticipates a formal response from MHRA within 30 days of the resubmission, with CEO Iain D. Dukes expressing confidence that the updated package will support the study and provide important proof of concept data for TXM as an oral prophylaxis medicine.

Traws Pharma, Inc. announced it is preparing an updated toxicology data package for tivoxavir marboxil (TXM) to address requirements from the UK's MHRA. This package is for a planned Phase 2a human influenza Challenge study and is expected to be resubmitted in Q3 2026. The company anticipates a formal response from the MHRA within 30 days of resubmission, expressing confidence that the updated data will support the proposed study.

Traws Pharma, Inc. announced the deferral of its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM). This decision follows a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). Despite the setback, the company maintains that TXM retains potential for emergency use in bird flu outbreaks and is actively advancing alternative influenza antiviral candidates. Traws Pharma remains committed to developing long-acting influenza antivirals, with a cash runway extending to Q1 2027, and is designing new candidates to address regulatory concerns while preserving efficacy.

Traws Pharma, Inc. announced the deferral of its planned Phase 2a human influenza challenge study for tivoxavir marboxil. This decision follows a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA). Despite this setback, the company remains committed to advancing long-acting influenza antivirals, noting tivoxavir marboxil's potential for emergency use in bird flu outbreaks and is actively developing alternative candidates. The company's cash runway is projected to extend to Q1 2027.

Traws Pharma, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on July 8, 2026. Stockholders will vote on several key proposals, including the election of seven directors, an amendment to the 2021 Incentive Compensation Plan to increase available shares by 2,000,000, and the ratification of KPMG LLP as the independent auditor. Additionally, stockholders will consider approving the issuance of common stock upon the exercise of Series B and Series C Warrants. The Board of Directors recommends voting "For" all proposals.

Traws Pharma, Inc. announced the advancement of a novel proprietary broad-spectrum combination antiviral agent targeting ongoing Hantavirus and Ebola Virus disease outbreaks, with potential utility against Lassa. The therapy utilizes a unique "dual-strike" mechanism to hijack host cell pathways for viral eradication, with both components previously evaluated safely in human studies. The company is concurrently scaling up manufacturing and engaging with the US CDC, Nigerian NAFDAC, and the African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and global access.

Traws Pharma, Inc. announced the advancement of a novel proprietary broad-spectrum combination anti-viral agent. This investigational therapy utilizes a unique "dual-strike" mechanism to combat critical global viral threats like Hantavirus, Ebola, and Lassa. The company is concurrently scaling up manufacturing and engaging with health agencies, including the CDC, NAFDAC, and AMA, to fast-track clinical development, ensure emergency supply, and establish local manufacturing in Nigeria for global access.

Traws Pharma, Inc. announced an update to its At The Market (ATM) Offering Agreement with Citizens JMP Securities, LLC. The company may now offer and sell shares of its common stock with an aggregate offering price of up to $3,128,399. This updated limit reflects the company's current "baby shelf" limitation under General Instruction I.B.6. of Form S-3, utilizing its effective shelf registration statement and recent prospectus supplements.